NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
P/B ratio for NanoViricides, Inc. (NNVC)
P/B ratio as of 2024: 1.92
According to NanoViricides, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.92. At the end of 2023 the company had a P/B ratio of 0.90.
P/B ratio history for NanoViricides, Inc. from 2005 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 1.92 |
| 2023 | 0.90 |
| 2022 | 0.94 |
| 2021 | 1.69 |
| 2020 | 1.93 |
| 2019 | 1.61 |
| 2018 | 1.62 |
| 2017 | 3.99 |
| 2016 | 4.00 |
| 2015 | 3.08 |
| 2014 | 7.58 |
| 2013 | 4.07 |
| 2012 | 1.73 |
| 2011 | 4.69 |
| 2010 | 10.30 |
| 2009 | 7.56 |
| 2008 | 104.05 |
| 2007 | 58.97 |
| 2006 | 38.00 |
| 2005 | -216.43 |